Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)

The Beacon
11/12/2017 8 min
Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)

Listen "Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS) testing of all solid tumors, ushering in a new era of growing precision medicine and molecular oncology.

More episodes of the podcast The Beacon

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075) 08/03/2019
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074) 05/03/2019
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073) 28/12/2018
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072) 21/12/2018
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071) 11/12/2018
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070) 09/12/2018
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069) 04/12/2018
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068) 02/12/2018
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067) 16/11/2018
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066) 14/11/2018
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA